Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenePHIT AB-1002 in non-ischemic heart failure
NL-OMON59898Phase 2Active, not recruiting
- Sponsor
- AskBio
- Start
- Nov 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and Non-Ischaemic Cardiomyopathy (NICM) comparing AB-1002 with Placebo infusion (2 arms). Primary endpoints: Modified Win Ratio at 52 weeks, Treatment-emergent adverse events and serious adverse events and 3 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
NAN-101
03
Conditions
heart failure (HF)Non-Ischaemic Cardiomyopathy (NICM)
Beyond the preview
Go deeper on NL-OMON59898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59898.